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Abstract
Background: Stress ulcer prophylaxis is considered standard of care in many critically ill patients in the intensive
care unit (ICU). However, the quality of evidence supporting this has recently been questioned, and clinical
equipoise exists. Whether there is overall benefit or harm of stress ulcer prophylaxis in adult hospitalised acutely ill
patients is unknown. Accordingly, we aim to assess patient-important benefits and harms of stress ulcer prophylaxis
versus placebo or no treatment in adult hospitalised acutely ill patients with high risk of gastrointestinal bleeding
irrespective of hospital setting.
Methods/design: We will conduct a systematic review of randomised clinical trials with meta-analysis and trial
sequential analysis and assess use of proton pump inhibitors (PPIs) or histamine-2-receptor antagonists (H2RAs) in
any dose, formulation and duration. We will accept placebo or no prophylaxis as control interventions. The
participants will be adult hospitalised acutely ill patients with high risk of gastrointestinal bleeding.
We will systematically search the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, BIOSIS and Epistemonikos
for relevant literature. We will follow the recommendations by the Cochrane Collaboration and the Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA) statement. The risk of systematic errors (bias) and random
errors will be assessed, and the overall quality of evidence will be evaluated using the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) approach.
Discussion: There is a need for a high-quality systematic review to summarise the benefits and harms of stress ulcer
prophylaxis in hospitalised patients to inform practice and future research. Although stress ulcer prophylaxis is used
worldwide, no firm evidence for benefit or harm as compared to placebo or no treatments has been established.
Critical illness is a continuum not limited to the ICU setting, which is why it is important to assess the benefits and
harms of stress ulcer prophylaxis in a wider perspective than exclusively in ICU patients.
Systematic review registration: PROSPERO CRD42017055676
Keywords: Acid suppressants, Gastrointestinal bleeding, Risk factors, Side effects, Stress ulcer prophylaxis, Proton pump
inhibitors, Histamine-2-receptor antagonists
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Background
Description of the condition
Critically ill patients are at risk of stress-related mucosal
damage [1]. After 3 days of stay in the intensive care
unit (ICU), the majority of patients have developed
endoscopically evident signs of gastrointestinal ulcera-
tions [2, 3]. These stress ulcerations are typically superfi-
cial and asymptomatic, but 1 in 20 will progress and
erode larger vessels resulting in overt gastrointestinal
bleeding [4, 5]. Gastrointestinal bleeding is a potentially
life-threatening condition with a mortality of up to 50%
among frail patients [6]. However, the reported preva-
lence of gastrointestinal bleeding varies between 2 and
5% possibly because of heterogeneous populations, vary-
ing definitions and difficulties in diagnosing stress ulcers
[5, 7–10]. Importantly, the reported estimates often in-
clude all conditions resulting in gastrointestinal bleeding
and not exclusively stress ulcers and other bleedings pre-
vented by acid suppressants. In a cohort study by Cook
et al. [11], stress ulceration was identified as the sole
source of gastrointestinal bleeding by endoscopy in less
than 50% of the patients, suggesting that other causes of
gastrointestinal bleeding, not prevented by stress ulcer
prophylaxis, are frequent. This highlights the need for
placebo-controlled trials to ensure assessment of stress
ulcer-induced bleedings only.
Several studies have sought to identify risk factors for
developing gastrointestinal bleeding in critically ill
patients. A 1994 landmark study highlighted mechanical
ventilation (for >48 h) and coagulopathy as major risk
factors for gastrointestinal bleeding [6]. Later studies,
however, have not consistently been able to reproduce
the association with mechanical ventilation [5, 8].
Recently, acute kidney injury, hepatic failure and acute
and chronic disease severity have also been suggested as
important risk factors [5, 8, 12].
Description of the intervention
In order to prevent the potential progression from
stress-related mucosal damage to gastrointestinal bleed-
ing, stress ulcer prophylaxis was introduced more than
40 years ago [13]. Initially, antacids and later sucralfate
were the preferred agents. The introduction of
histamine-2-receptor antagonists (H2RAs) made intra-
venous administration possible. A randomised clinical
trial (RCT) from 1998 by Cook et al. reported a lower
incidence of gastrointestinal bleeding in patients receiv-
ing H2RA compared with sucralfate [14]. Proton pump
inhibitors (PPIs) were introduced later on, and today,
the majority of prescribed stress ulcer prophylaxis is
H2RAs or PPIs [5, 15].
International guidelines recommend the use of stress
ulcer prophylaxis with PPI or H2RA as standard of care
in high-risk ICU patients [16]. However, the rationale
and level of evidence of stress ulcer prophylaxis in ICU
patients has been questioned because of limited data,
methodological flaws in some trials, potential increased
rates of hospital-acquired pneumonia, Clostridium diffi-
cile enteritis and myocardial ischemia following the use
of stress ulcer prophylaxis, and general improvements in
intensive care [1, 17–19].
How the intervention might work
It has been hypothesised that stress ulcerations are
caused by decreased mucosal blood flow, ischemia and
reperfusion injury and hence are less related to acid
secretion than peptic ulcerations [20]. However, the
pathophysiology behind stress ulcerations has not been
fully elucidated.
H2RAs inhibit the stimulation of the H+-K+-adeno-
sine triphosphatase (ATPase) by binding to the H2-
receptor on the parietal cells [21]. This results in
diminished gastric acid secretion. H2RAs can be
administered enterally or intravenously, and continu-
ous intravenous infusion seems to be more effective
than bolus injections at controlling gastric pH [22].
PPIs are among the most frequently prescribed drugs
in the world [21]. They inhibit secretion of gastric
acid by forming irreversible disulfide bonds with the
H+-K+-ATPase pump. This leads to inhibition of the
secretion of gastric acid. PPIs can be administered en-
terally or intravenously, and the irreversible bond pro-
vides a stronger and more prolonged reduction of
acid secretion compared to H2RAs [21].
Why it is important to do this review
The effects of PPIs and H2RAs have been compared in
several RCTs and meta-analyses [17, 23–26], with the
latest indicating that PPIs results in better protection
against both clinically important and overt gastrointes-
tinal bleeding compared with H2RAs [26]. However, as
neither PPIs nor H2RAs have been found superior to
placebo, this might be of questionable clinical relevance.
In the most recent systematic review of stress ulcer
prophylaxis (PPI or H2RA) versus placebo or no prophy-
laxis in general ICU patients (20 trials), it was concluded
that the quantity and quality of evidence supporting the
use of stress ulcer prophylaxis is low with no firm
evidence for benefit or harm [27].
Additional trials have [28–30] and may have been pub-
lished, and it is necessary to include these trial estimates
in a meta-analysis to provide an up-to-date assessment
on patient-important benefits and harms. Existing evi-
dence on benefits and harms of stress ulcer prophylaxis
mainly derives from trials conducted in the ICU [27].
Critical illness is a continuum not limited to the ICU
setting, which is why it is important to assess the bene-
fits and harms of stress ulcer prophylaxis in acutely ill
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patients with high risk of gastrointestinal bleeding not
limited to the ICU setting. Inclusion of non-ICU high-
risk patients may also add to the questioned role of
mechanical ventilation as a trigger of stress ulcers. Des-
pite the clinical equipoise, common beliefs and practices
across various medical specialties are that certain sub-
populations of acutely ill patients benefit from stress
ulcer prophylaxis [31].
The use of stress ulcer prophylaxis is a clinical di-
lemma. It remains unresolved whether acid suppressants
prevent stress-related gastrointestinal bleeding in acutely
ill patients. The prevalence of gastrointestinal bleeding is
low, and the balance between benefits and harms of
stress ulcer prophylaxis is unknown. Whether there is
overall benefit or harm of stress ulcer prophylaxis is am-
biguous, and to ensure patient safety, there is a need for
large, high-quality RCTs of stress ulcer prophylaxis
versus placebo and well-designed systematic reviews.
Objectives
We aim to assess patient-important benefits and harms
of stress ulcer prophylaxis versus placebo or no prophy-
laxis in adult hospitalised acutely ill patients with high
risk of gastrointestinal bleeding irrespective of hospital
setting.
Research question: does stress ulcer prophylaxis im-
prove patient-important outcomes in adult hospitalised
acutely ill patients with high risk of gastrointestinal
bleeding as compared with placebo or no prophylaxis?
Methods
Study design
We will conduct a systematic review of RCTs with meta-
analysis and trial sequential analysis (TSA) and follow
the recommendations by the Cochrane Collaboration
[32] and the Preferred Reporting Items for Systematic
Review and Meta-Analysis (PRISMA) statement [33].
Study registration
This protocol has been prepared according to the
Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P) guidelines [34]
(checklist included as Additional file 1), and the review
has been registered in the International Prospective
Register of Systematic Reviews (PROSPERO) (https://
www.crd.york.ac.uk/prospero/; registration number
CRD42017055676).
Criteria for considering studies for this review
Types of studies
RCTs will be included regardless of publication source,
status and language. Quasi-randomised trials and cross-
over trials will be excluded.
Types of participants
Adult hospitalised acutely ill patients (as defined by the
included trials) with high risk of gastrointestinal bleeding
including (but not limited to) medical and surgical ICU
patients, patients in intermediate care units, patients in
coronary care facilities, neurosurgical patients (head and
spine), cardiothoracic surgical patients, organ trans-
planted patients, major abdominal/vascular/orthopaedic
(pelvis and hip) surgery, burn injured patients (incl. ther-
mal injury), patients with active malignant haemato-
logical illness, patients with acute kidney injury, patients
with acute hepatic failure, patients receiving high dose
steroids (at least 0.3 mg/kg/day of prednisolone
equivalent) and patients with sepsis.
Trials including children (as defined by the original
trials) will be excluded unless data can be separately
extracted for adults only.
Types of interventions
 Experimental intervention: any type of PPI
(omeprazole, lansoprazole, dexlansoprazole,
esomeprazole, pantoprazole and rabeprazole) or H2RA
(nizatidine, famotidine, cimetidine and ranitidine) in
any dose, formulation, timing and duration
 Control intervention: placebo or no prophylaxis
Types of outcome measures
Primary outcomes
 All-cause mortality
 Proportion of participants with one or more serious
adverse event (SAE), defined as any untoward
medical occurrence that resulted in death, was life-
threatening or prolonged existing hospitalisation,
resulted in persistent or significant disability or any
important medical event, which may have
jeopardised the patient [35]
 Proportion of participants with ‘clinically important
gastrointestinal bleeding’ as defined in the included
trials (not including ‘overt GI bleeding’)
Secondary outcomes
 Proportion of participants with C. difficile enteritis
(yes/no), as defined in the included trials
 Proportion of participants with myocardial
infarction (yes/no), as defined in the included trials
 Proportion of participants with hospital-acquired
pneumonia (yes/no), as defined in the included trials
 Quality-of-life (any continuous scale used in the
included trials)
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Assessment time points All outcomes will primarily be
assessed at the time point closest to 90 days. Secondly,
we will assess all outcomes at the maximum time of
follow-up.
Search methods for identification of studies
Electronic searches
We will search the following electronic databases:
 Cochrane Library
 MEDLINE
 EMBASE
 Epistemonikos
 Science Citation Index
 BIOSIS
We will additionally search databases of ongoing trials
including Clinical-Trials.gov (http://clinicaltrials.gov/),
metaRegister of Controlled Trials (http://www.isrctn.com/
page/mrct), the EU Clinical Trials register (https://
www.clinicaltrialsregister.eu/) and the World Health
Organization (WHO) International Clinical Trials
Registry Platform Search Portal (http://apps.who.int/
trialsearch/).
The tentative Medline search strategy is available in
Additional file 2. To continuously identify newly
published studies, we will apply PubMed’s ‘My NCBI’
(National Center for Biotechnology Information) email
alert service. Before we submit the final review draft to
an international peer-reviewed journal, we will perform
an updated search on all specified databases. If we iden-
tify new trials, these will be assessed and if relevant
incorporated in our review before submission of the final
review draft. If we detect additional relevant keywords
during any of the electronic or other searches, we will
modify the electronic search strategies to incorporate
these terms and document the changes.
Searching other resources
We will hand-search the reference list of relevant trials
and other systematic reviews and meta-analyses on
stress ulcer prophylaxis in adult hospitalised acutely ill
patients.
Unpublished trials will be sought identified. Authors
will be contacted for additional data if relevant.
Data collection and analysis
Selection of studies
Two review authors (SM, AG or CTA) will independ-
ently screen the abstract, title or both, of every record
retrieved, to determine which trials should be assessed
further. We will assess all potentially relevant articles as
full text. We will resolve any discrepancies through con-
sensus or recourse to a third review author (MHM). If
resolving disagreement is not possible, the article will be
added to those ‘awaiting assessment’ and we will contact
study authors for clarification. We will present an
adapted PRISMA flowchart of study selection [33]; see
Additional file 3.
Data extraction and management
Two review authors (SM, AG or CTA) will independ-
ently extract information from each included trial using
a predefined data extraction form. The extracted infor-
mation will include trial characteristics (year of publica-
tion, duration, country), characteristics of the trial
participants (inclusion criteria and exclusion criteria),
type of intervention/control (name, dosing, duration
and route of administration), type of control (name,
dosing, duration and route of administration),
outcomes and risk of bias.
In the event of duplicate publications, companion
documents or multiple reports of a primary study, we
will maximise yield of information by comparing all
available data and use the most complete dataset ag-
gregated across all known publications. In case of
doubt, the publication reporting the longest follow-up
associated with our primary or secondary outcomes
will be given priority.
Assessment of risk of bias in included studies
We will assess the risk of systematic errors (bias) of
the included trials according to the Cochrane Hand-
book [32]. The assessment will be performed inde-
pendently by two authors (SM, AG or CA).
Disagreements will be resolved by consensus upon
consultation with a third author (MHM).
The following domains will be assessed: (1) random
sequence generation, (2) allocation concealment, (3)
blinding of participants and personnel, (4) blinding of
outcome assessment, (5) incomplete outcome data, (6)
selective reporting and (7) other bias, including base-
line imbalance, early stopping and bias due to vested
financial interest or academic bias. If one or more do-
mains are judged as being high or unclear, we will
classify the trial as having overall high risk of bias
[32]. We will assess the domains ‘blinding of outcome
assessment’, ‘incomplete outcome data’ and ‘selective
outcome reporting’ for each outcome. Thus, we will
be able to assess the bias risk for each result in
addition to each trial.
We will base our primary conclusions as well as
our presentation in the ‘Summary of findings table’
section on the results of our primary outcomes with
low risk of bias.
The risk of bias will be depicted in a ‘risk of bias
summary’ figure, reviewing the authors judgements
(according to the Cochrane handbook [32]) about
Marker et al. Systematic Reviews  (2017) 6:118 Page 4 of 8
each included risk of bias item for each included
study (red: high risk, green: low risk, yellow: unclear).
Measures of treatment effect
We will calculate relative risks (RRs) with 95% confi-
dence intervals (CIs) and mean differences (MDs) with
95% CIs for dichotomous outcomes and continuous
outcomes, respectively.
Dealing with missing data
The relevant authors will be sought contacted for miss-
ing outcome data. Sensitivity analysis using imputations
of missing outcome data of dichotomous outcomes in
best-worse and worse-best case scenarios will be
performed assuming:
1) All patients lost to outcome assessment (follow-up)
in the intervention group did not experience the
outcome of interest, while all patients lost to
outcome assessment (follow-up) in the control
group did experience the outcome of interest.
2) All patients lost to outcome assessment (follow-up)
in the intervention group did experience the
outcome of interest, while all patients lost to
outcome assessment (follow-up) in the control
group did not experience the outcome of interest.
When analysing continuous outcomes with missing
data, we will use imputations of missing outcome data
in best-worse and worse-best case scenarios [36]
assuming:
1) All patients lost to outcome assessment (follow-up)
in the intervention group have an outcome being
the group mean plus two standard deviations (SDs)
of the group mean, and all patients lost to outcome
assessment (follow-up) in the control group will be
the group mean minus two SDs.
2) All patients lost to outcome assessment (follow-up)
in the intervention group have an outcome being
the group mean minus two SDs of the group mean,
and all patients lost to outcome assessment (follow-
up) in the control group will be the group mean
plus two SDs.
Assessment of heterogeneity
Based on a previous systematic review and meta-analysis
where statistical and clinical heterogeneity was limited,
we plan to report pooled effect estimates [27]. We will
primarily inspect forest plot for signs of statistical
heterogeneity. We will secondly use D-squared and I-
squared statistics to describe heterogeneity among the
included trials. We will use and report a fixed-effect
model if I-squared = 0 and use and report the results of
both random-effects model and fixed-effect model if I-
squared >0. We will report the most conservative esti-
mate if the intervention effects differ in the two models
and the broadest confidence interval if they concur [36].
Assessment of reporting bias
We will use a funnel plot to assess reporting bias if ten
or more trials are included. For dichotomous outcomes,
we will test asymmetry with the Harbord test [37]. For
continuous outcomes, we will use the regression asym-
metry test [38] and the adjusted rank correlation [39].
Data synthesis
We will use Review Manager Software (RevMan 5.3) as
statistical software.
We will calculate summary estimates (conventional
meta-analyses) as outlined above. We will use and report
results based on the analysis of intention-to-treat popu-
lations if available.
Trial sequential analysis
We will conduct TSA in order to assess the risk of ran-
dom errors [40–42]. Cumulative meta-analyses are at
risk of producing random errors due to sparse data and
multiple testing of accumulating data [32, 43–50]. TSA
allows to estimate the required information size (the
number of participants) needed to detect or reject an a
priori pre-specified realistic intervention effect in a
meta-analysis and the TSA-adjusted CIs [51, 52]. The re-
quired information size will take into account the event
proportion in the control group, the assumption of a
plausible RR reduction and the heterogeneity variance of
the meta-analysis [52, 53]. We will use conservative esti-
mations of the anticipated intervention effect estimates
to reduce the risk of random error [36]. In brief, as we
have three co-primary outcomes and four secondary
outcomes, we will consider a P < 0.025 and P < 0.020 as
statistically significant, respectively [35].
We will apply trial sequential monitoring boundar-
ies according to an a priori 15% relative risk differ-
ence (reduction or increase), with a family-wise error
rate (FWER) equal to an alfa of 5%, beta 90% and a
control event proportion suggested by all the trials
reporting the outcome in question. TSA-adjusted CIs
will be provided [42].
Subgroup analysis and investigation of heterogeneity
We will use Chi-squared test to provide an indication of
heterogeneity between trials, with P = 0.10 considered
significant.
We plan to conduct the following subgroup analyses:
1. Comparing estimates of the pooled intervention
effect in trials with overall low risk of bias vs. overall
Marker et al. Systematic Reviews  (2017) 6:118 Page 5 of 8
high risk of bias. Hypothesised direction of sub-group
effect: increased beneficial intervention effect in the
trials with overall high risk of bias
2. Comparing estimates of the pooled intervention
effect in trials using PPI vs. H2RA. Hypothesised
direction of sub-group effect: increased beneficial
intervention effect in trials using PPI
3. Comparing estimates of the pooled intervention effect
in trials using placebo vs. no treatment. Hypothesised
direction of sub-group effect: increased beneficial
intervention effect in trials using no treatment
4. Comparing estimates of the pooled intervention
effect in the included subpopulations of adult
hospitalised acutely ill patients. Hypothesised
direction of sub-group effect: increased beneficial
intervention effect in some subpopulations
5. Comparing estimates of the pooled intervention effect
in ICU patients vs. non-ICU patients. Hypothesised
direction of sub-group effect: increased beneficial
intervention effect in ICU patients vs. non-ICU
patients
Sensitivity analysis
We will conduct sensitivity analysis by performing
empirical continuity adjustments in the zero event trials.
Summary of findings table
We will assess the overall quality of evidence for each
outcome measure according to the Grading of Recom-
mendations Assessment, Development, and Evaluation
(GRADE) approach [54]. In brief, we will downgrade the
quality of evidence (our confidence in the effect-
estimates) for an intervention for identified risks of bias,
inconsistency (unexplained heterogeneity), indirectness
(including other patient populations or use of surrogate
outcomes), imprecision (wide confidence interval around
the effect estimate) and publication bias. Accordingly,
the overall quality of evidence will be rated ‘high’, ‘moder-
ate’, ‘low’ or ‘very low’.
Discussion
This systematic review will provide updated important
knowledge on use of stress ulcer prophylaxis in adult
hospitalised acutely ill patients irrespective of hospital
setting. We will include recently published RCTs and in-
clude and assess adult hospitalised acutely ill patients
with high risk of gastrointestinal bleeding both in- and
outside the context of the ICU.
New RCTs may have provided important new data on
the potential harm of stress ulcer prophylaxis, including
the risk of cardiovascular events, hospital-acquired
pneumonia and C. difficile infections, which is why an
updated systematic review is warranted.
As critical illness is not restricted to ICU patients,
we believe a wider scope is mandated in order to
more accurately evaluate the attempted prevention of
gastrointestinal bleedings due to stress ulcers. In a
recent cohort study [5], the incidence of gastrointes-
tinal bleedings peaked on the first 1–2 days of ICU
stay, suggesting that the risk of developing stress
ulcerations and gastrointestinal bleeding in acutely ill
patients is not limited to the ICU setting, but is a
continuum not defined by the clinical setting. Conse-
quently, an assessment of benefits and harms of stress
ulcer prophylaxis in high-risk patients irrespective of
clinical setting is needed.
Using TSA to assess the risk of random errors will
increase the validity of the summary estimates calculated.
The risk of type I errors (a false positive finding) are in-
creased when multiple testing is done, e.g. when analysing
multiple primary and secondary outcomes, during re-
peated testing of data, and, importantly, when meta-
analyses are conducted and updated [46]. Also, the risk of
type II errors (a false negative finding) challenge the re-
sults of meta-analyses, due to sparse data. Statistically sig-
nificant meta-analyses with few participants have low
reliability, and the interventional effect is often overrated
[45, 53]. Furthermore, TSA allows to estimate if the
required information size (sample size) has been reached
and if additional trials are needed [45, 46, 49, 50].
Finally, this systematic review may aid data monitoring
and safety committees when assessing results of interim
analyses of ongoing and upcoming trials on stress ulcer
prophylaxis in acutely ill patients (SUP-ICU [55],
REVISE [56], PEPTIC [57]). A modern data monitoring
and safety committee cannot allow themselves to con-
clude solely on the data provided from the interim-
analysis within a specific single trial as evidence from
the ‘outside’ may influence the overall decision of
whether the trial shall continue or not. Therefore, to
properly summarise the evidence provided before and
during the trial, the data monitoring and safety commit-
tee must include the interim-part of the trial data in
meta-analyses of all the evidence provided so far using
e.g. TSA to reach realistic and firm results for the actual
achieved evidence.
Today, stress ulcer prophylaxis with PPI or H2RA is
recommended in international guidelines and regarded
as standard of care in adult ICU patients [16]. However,
the quantity and quality of evidence supporting use of
stress ulcer prophylaxis in ICU patients is low with no
firm evidence for benefit or harm, and clinical equipoise
exist [1, 17–20]. The outlined systematic review will pro-
vide important data on the benefits and harms of stress
ulcer prophylaxis in adult hospitalised acutely ill patients
with high risk of gastrointestinal bleeding in and outside
the context of the ICU.
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